Compare Neurocrine Biosciences Inc (NBIX) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Rush Street Interactive Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Rush Street Interactive Inc trades at $26.65 (market cap $3.12B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.1× Rush Street Interactive Inc's market cap. Which is the better fit depends on your goals.
| NBIX | RSI | |
|---|---|---|
Market Cap | $15.77B | $3.12B |
Sector | Health | Technology |
52-Week High | $185.50 | $34.52 |
52-Week Low | $123.10 | $15.89 |
Enterprise Value | $15.78B | $2.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Rush Street Interactive (RSI) trades at $27.02, up 1.27% today, with a bullish technical signal from moving averages and strong institutional interest. Recent Q2 2026 results showed record revenue of $393.8 million and net income of $29.3 million, beating EPS expectations. The company raised full-year 2026 guidance, reflecting robust growth in online casino and sports betting markets. Analyst consensus is strongly bullish with a $34.75 price target, indicating 29% upside potential from current levels.
The outlook for RSI is positive, driven by accelerating revenue growth and expanding market share, but risks include intense competition and regulatory scrutiny in the gambling sector. High valuation multiples like a P/E of 87.16 suggest elevated expectations, requiring continued execution. Institutional buying, such as BlackRock's $448 million investment in Q2 2026, supports confidence, though investors should monitor margin pressures from rising marketing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
